Semaglutide is the active ingredient, and Ozempic is one of its brand names. There’s no pharmacological difference between them. Ozempic is simply the product that Novo Nordisk manufactures and sells containing semaglutide for specific medical uses. Think of it like ibuprofen and Advil: one is the drug, the other is the brand.
Where it gets more nuanced is that semaglutide is sold under several different brand names, each approved for different conditions and delivered in different ways. And a growing market of compounded semaglutide products adds another layer of complexity worth understanding.
Three Brands, One Drug
Semaglutide is currently sold under three FDA-approved brand names, each with distinct approved uses:
- Ozempic is a once-weekly injection approved for adults with type 2 diabetes. It’s indicated to improve blood sugar control, reduce the risk of heart attack and stroke in people with established cardiovascular disease, and slow kidney disease progression. It was first approved in 2017.
- Wegovy is also a once-weekly injection, but it’s approved specifically for weight management in adults and children aged 12 and older, alongside diet and exercise.
- Rybelsus is an oral tablet taken daily, approved for blood sugar management in type 2 diabetes. It is not approved for weight loss.
All three contain the same molecule. The differences are the dose, the delivery method, and what the FDA has reviewed and approved each one to treat. Ozempic is not FDA-approved for weight loss, even though it’s widely prescribed off-label for that purpose.
How Semaglutide Works in the Body
Semaglutide mimics a hormone your gut naturally produces after eating called GLP-1. Normally, this hormone breaks down within minutes. Semaglutide is engineered to last much longer, which is why a single weekly injection can work continuously.
It affects blood sugar through several pathways at once. It prompts your pancreas to release more insulin when blood sugar is elevated, suppresses a competing hormone called glucagon that raises blood sugar, and slows the rate at which your stomach empties food into your intestines. That slower digestion is partly why people feel full longer after meals.
The appetite-suppressing effects go beyond the gut. Semaglutide acts on brain regions that control hunger and food reward. In one area of the brainstem that sits outside the blood-brain barrier, it reduces the pleasurable response to eating. In the hypothalamus, it shifts the balance between hunger-promoting and fullness-promoting chemical signals, resulting in less appetite and slightly higher energy expenditure. The combined effect is that people on semaglutide simply want to eat less, often without consciously trying.
Blood Sugar and Heart Benefits
In clinical trials, Ozempic lowered A1C (a measure of average blood sugar over roughly three months) by about 1.5 to 1.8 percentage points at typical maintenance doses. For context, dropping A1C by even one full point significantly reduces the risk of diabetes complications, so these are meaningful reductions.
The cardiovascular data is notable. In a major trial of over 3,000 people with type 2 diabetes and high cardiovascular risk, those taking semaglutide by injection had a 26% lower rate of major cardiovascular events (heart attack, stroke, or cardiovascular death) compared to placebo over two years. Nonfatal stroke dropped by 39%. A pooled analysis combining injection and oral semaglutide data showed a 24% overall reduction in major cardiovascular events. These results contributed to Ozempic’s expanded FDA indication for heart risk reduction.
How Ozempic Is Taken
Ozempic comes as a prefilled injection pen. You inject it once a week under the skin of your abdomen, thigh, or upper arm, rotating the injection site each time. A new needle is used with each dose.
The dosing follows a gradual ramp-up schedule. You start at 0.25 mg weekly for the first four weeks, which is meant to let your body adjust and isn’t considered a therapeutic dose. At week five, the dose increases to 0.5 mg. From there, your provider may increase to 1 mg and eventually up to 2 mg weekly, depending on how well your blood sugar responds. Each step up requires at least four weeks at the current dose. The maximum is 2 mg per week.
Ozempic also recently became available as an oral tablet, with a different dosing schedule: 1.5 mg daily for the first month, then 4 mg daily, with an option to go up to 9 mg daily if needed.
Compounded Semaglutide Is Not the Same
The growing demand for semaglutide has created a market for compounded versions, which are mixed by compounding pharmacies rather than manufactured by Novo Nordisk. These products claim to contain the same active ingredient but are not FDA-approved, meaning no federal agency has verified their safety, effectiveness, or quality before sale.
The FDA has raised specific concerns. Some compounding pharmacies have been using salt forms of semaglutide (like semaglutide sodium or semaglutide acetate) that are chemically different from the base form used in Ozempic. The FDA has stated it has no data confirming these salts behave the same way in the body and sees no lawful basis for their use in compounding.
Dosing errors have been another problem. The FDA has received multiple reports of adverse events, some requiring hospitalization, linked to patients measuring incorrect doses of compounded injectable semaglutide. In some cases, healthcare professionals miscalculated doses. Others involved doses exceeding what the FDA-approved labeling recommends. Counterfeit Ozempic pens have also appeared on the U.S. market, which may contain wrong amounts of the active ingredient or none at all.
If you’re considering a compounded semaglutide product because of cost or availability, the key distinction is that you’re getting a product with no regulatory guarantee of what’s inside. That’s a fundamentally different risk profile from taking a branded, FDA-approved medication.
Why the Confusion Exists
Most of the confusion stems from semaglutide’s unusual situation: one molecule, multiple brands, and a massive off-label prescribing trend. Ozempic became a household name largely because of its weight loss effects, even though that’s not what it’s approved for. Wegovy is the weight loss version, but supply shortages pushed many people toward Ozempic or compounded alternatives instead.
The practical takeaway is straightforward. Semaglutide is the drug. Ozempic, Wegovy, and Rybelsus are three different products containing that drug, each designed and approved for specific uses. Compounded semaglutide is an unregulated alternative that carries additional risks. If your provider prescribes “semaglutide,” the brand you receive depends on what condition is being treated, how your insurance covers it, and what’s currently in stock.